Evaluation of the polyclonal ELISA HPV serology assay as a biomarker for human papillomavirus exposure

Sarah E. Coseo, Carolina Porras, Lori E. Dodd, Allan Hildesheim, Ana Cecilia Rodriguez, Mark Schiffman, Rolando Herrero, Sholom Wacholder, Paula Gonzalez, Mark E. Sherman, Silvia Jimenez, Diane Solomon, Catherine Bougelet, Leen Jan Van Doorn, Wim Quint, Mahboobeh Safaeian

Research output: Contribution to journalArticle

13 Scopus citations

Abstract

Background: Seropositivity to human papillomavirus (HPV)16 and 18 antibodies is used as a measure of cumulative HPV exposure and as a stratifier of HPV exposure for vaccine efficacy analyses. Overall performance of these assays, as a measure of HPV exposure, has not been evaluated. Methods: Using data from the enrollment phase of the HPV16/18 vaccine trial in Costa Rica, we evaluated the performance of the polyclonal enzyme-linked immunosorbent assay (ELISA) HPV16 and 18 serological assays as a measure of HPV exposure. Biologic (e.g., HPV infection at the cervix) and behavioral characteristics (e.g., lifetime number of sexual partners) with known associations with current and past HPV infection were used to define cases and controls (HPV exposed vs. not exposed). Prevaccination serum was measured for antibodies against HPV16 and 18 by ELISA; cervical samples were tested for HPV DNA using PCR SPF10/LiPA25. ELISA results were analyzed using receiver-operator characteristic curves; performance was evaluated at the manufacturer set cut point (HPV16 = 8, HPV18 = 7) and at cut points chosen to optimize sensitivity and specificity (HPV16 = 34, HPV18 = 60). RESULTS:: Defining cases as type-specific HPV DNA positive with high-grade abnormal cytology (i.e., combined molecular and microscopic markers of infection), HPV16-ELISA gave sensitivity that was lower at the optimal cut point than the manufacturer cut point (62.2 compared with 75.7, respectively; P = 0.44). However, specificity was higher (85.3 compared with 70.4, respectively; P < 0.0001). Similarly, HPV18-ELISA gave sensitivity that was lower at the optimal cut point than the manufacturer cut point (34.5 compared with 51.7, respectively; P = 0.40), with higher specificities (94.9 compared with 72.6, respectively; P < 0.0001). Conclusions: Modifying cut points did not improve the low sensitivity. The low sensitivity of this assay does not support its use for risk stratification or clinical settings.

Original languageEnglish (US)
Pages (from-to)976-982
Number of pages7
JournalSexually Transmitted Diseases
Volume38
Issue number10
DOIs
StatePublished - Oct 2011

ASJC Scopus subject areas

  • Dermatology
  • Public Health, Environmental and Occupational Health
  • Microbiology (medical)
  • Infectious Diseases

Fingerprint Dive into the research topics of 'Evaluation of the polyclonal ELISA HPV serology assay as a biomarker for human papillomavirus exposure'. Together they form a unique fingerprint.

  • Cite this

    Coseo, S. E., Porras, C., Dodd, L. E., Hildesheim, A., Rodriguez, A. C., Schiffman, M., Herrero, R., Wacholder, S., Gonzalez, P., Sherman, M. E., Jimenez, S., Solomon, D., Bougelet, C., Van Doorn, L. J., Quint, W., & Safaeian, M. (2011). Evaluation of the polyclonal ELISA HPV serology assay as a biomarker for human papillomavirus exposure. Sexually Transmitted Diseases, 38(10), 976-982. https://doi.org/10.1097/OLQ.0b013e31822545c0